Form 4 for PLUR Pluri Inc.
Accepted 2022-02-14 00:00:00 ET · period of report 2022-02-10 · accession 0001213900-22-007471 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-02-14 | 2022-02-10 | PLUR | Aberman Zami | Dir | P - Purchase | $1.80 | +80.6K | 91.8K | +724% | +$145.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-10 | P | A | 80,616 | $1.80 | 91,756 | I By Rose Hitech Ltd. | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the Tel Aviv Stock Exchange in New Israeli Shekels (NIS), at per share purchase prices ranging from NIS 5.70 to NIS 5.90, inclusive, or ranging from $1.77 to $1.82 in U.S. Dollars, inclusive (based on an exchange rate of NIS 3.221 per U.S. dollar). The Reporting Person undertakes to provide to Pluristem Therapeutics Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). |